Neurologic Disorders Therapeutics Market: Current Analysis and Forecast (2022-2028)

The global neurologic disorders therapeutics Market is expected to grow at a significant rate of around 5% during the forecast period. Neurologic disorder is a disorder of the nervous system. As per various studies, the growth of these neurological disorders is spreading rapidly across the world and becoming increasingly common, especially neurodegenerative diseases. Furthermore, Neurologic disorders therapeutics is expected to have the fastest growth rate in the market mainly due to the availability of skilled healthcare professionals, and the safety & efficacy during the treatment procedures. Moreover, the growing patient pool suffering from neurovascular diseases such as brain aneurysms, and arteriovenous malformations are also contributing to the growth of this market during the forecast period. For instance, according to the Brain Aneurysms Foundation, about 30,000 people in the United States suffer a brain aneurysm rupture each year.

AbbVie Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst disease type, neurodegenerative diseases category to witness robust CAGR during the forecast period"

Based on disease type, the market is segmented into neurovascular diseases, CNS trauma, neurodegenerative diseases, infectious diseases, CNS cancer, and others. The neurodegenerative diseases category is to witness considerable growth during the forecast period. This is mainly due to the increasing brain injuries, cerebral disorders, and rising prevalence of hypertension in the geriatric population are the major factors for the growth of the neurologic disorder's therapeutics market during the forecast period. For instance, according to the Brain Aneurysm Foundation, an estimated 6 million Americans are affected by cerebral aneurysms.

"Amongst drug class, the antiepileptics to hold a significant share in the market in 2020"

On the basis of drug class, the market is categorized into analgesics, anesthetics, anticonvulsants, antiepileptics, antiparkinson agents, and others. Among these, the antiepileptics category is to witness significant growth during the forecast period. This is mainly due to these drugs prevent seizures, either by decreasing excitation or enhancing inhibition. Moreover, the growing prevalence of epilepsy demanding for therapeutically effective medications is creating pressure among the market players to introduce AEDs. For instance, in January 2020, Eisai Co. Ltd. announced the launch of FYCOMPA in China for the treatment of partial-onset seizures in patients aged 12 years and older.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the neurologic disorders therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is expected to witness significant growth in the market owing to the availability of market players in the region and the rising initiative undertaken by key players to develop various therapies for different neurological disorders are the major factors that are expected to increase the market share. Moreover, the growing cases of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer's, Parkinson's disease, and brain cancer is fueling the demand for neurologic disorders therapeutics in the region. For instance, around 70,800 people in the United States are diagnosed with brain cancer every year, which represents 1.4% of the total cancer incidence and causes about 2.4% of all cancer deaths in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

The global neurologic disorders therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.